Anticancer drugs that target proteins involved in tumour angiogenesis ... with VEGF inhibitors. Taken together, these properties indicate that α-PlGF is a promising anti-angiogenic agent.

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

In this report, we will discuss some of the AACR data relating to angiogenesis in light of previous results from clinical trials, attempting to outline what has been achieved so far and what are ...

Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and ... challenges associated with anti-VEGF use, review the rationale ...